H. Tsao, M. B. Atkins, and A. J. Sober, Management of cutaneous melanoma, N Engl JMed, vol.351, pp.998-1012, 2004.

L. Quillienv and L. Toujas, Vaccinal cell therapy in melanoma, Bull Cancer, vol.90, pp.722-755, 2003.

T. Lesimple, A. Moisan, and A. Carsin, Injection by various routes of melanoma antigen-associated macrophages: biodistribution and clinical effects, Cancer Immunol Immunother, vol.52, pp.438-482, 2003.

H. Jonuleit, A. Giesecke-tuettenberg, and T. Tuting, A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection, Int J Cancer, vol.93, pp.243-51, 2001.

B. Schuler-thurner, E. S. Schultz, and T. G. Berger, Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocytederived dendritic cells, JExp Med, vol.195, pp.1279-88, 2002.

P. Kalinski, C. M. Hilkens, A. Snijders, F. G. Snijdewint, and M. L. Kapsenberg, IL-12-deficient dendritic cells, generated in the presence of prostaglandin E 2 , promote type 2 cytokine production in maturing human naive T helper cells, J Immunol, vol.159, pp.28-35, 1997.

E. Klechevsky, H. Kato, and A. M. Sponaas, Dendritic cells star in Vancouver, J Exp Med, vol.202, pp.5-10, 2005.

C. Boccaccio, S. Jacod, and . Kaisera, Identification of a clinical-grade maturation factor for dendritic cells, J Immunother, vol.25, pp.88-96, 2002.

C. M. Balch and N. Cascinelli, The new melanoma staging system, Tumori, vol.87, pp.64-72, 2001.

B. Goxe, N. Latour, M. Chokri, J. P. Abastado, and M. Salcedo, Simplified method to generate large quantities of dendritic cells suitable for clinical applications, Immunol Invest, vol.29, pp.319-355, 2000.

B. Widner, E. R. Werner, H. Schennach, H. Wachter, and D. Fuchs, Simultaneous measurement of serum tryptophan and kynurenine by HPLC, Clin Chem, vol.43, pp.2424-2430, 1997.

M. A. Quillienv and A. Carsin, Biodistributionof radiolabelled human dendritic cells injected by various routes, EurJNucl Med Mol Imaging, vol.32, pp.731-772, 2005.

M. Bodinier, M. A. Peyrat, and C. Tournay, Efficient detection and immunomagnetic sorting of specific T cells using multimers of MHC class I and peptide with reduced CD8 binding, Nat Med, vol.6, pp.707-717, 2000.

, Cancer Therapy: Clinical www.aacrjournals.org

, Clin Cancer Res, vol.12, issue.24, p.7388, 2006.

E. A. Gehan, The determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent, J Chronic Dis, vol.13, pp.346-53, 1961.

M. Salcedo, N. Bercovici, and R. Taylor, Vaccination of melanoma patients using dendritic cells loaded with an allogeneic tumor cell lysate, Cancer Immunol Immunother, vol.55, pp.819-848, 2006.

W. Jongmans, D. M. Tiemessen, I. J. Van-vlodrop, P. F. Mulders, and E. Oosterwijk, Th1-polarizing capacity of clinical-grade dendritic cells is triggered by Ribomunyl but is compromised by PGE 2 : the importance of maturation cocktails, J Immunother, vol.28, pp.480-487, 2005.

J. C. Peng, R. Thomas, and L. K. Nielsen, Generation and maturation of dendritic cells for clinical application under serum-free conditions, J Immunother, vol.28, pp.599-609, 2005.

I. J. De-vries, W. J. Lesterhuis, and J. O. Barentsz, Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy, Nat Biotechnol, vol.23, pp.1407-1420, 2005.

T. Lesimple, A. Moisan, and L. Toujas, Autologous human macrophages and anti-tumour cell therapy, Res Immunol, vol.149, pp.663-71, 1998.

D. Dieckmann, E. S. Schultz, and B. Ring, Optimizing the exogenous antigen loading of monocyte-derived dendritic cells, Int Immunol, vol.17, pp.621-656, 2005.

D. Schadendorf and F. O. Nestle, Autologous dendritic cells for treatment of advanced cancer-an update, Recent Results Cancer Res, vol.158, pp.236-284, 2001.

J. Banchereau, A. K. Palucka, and M. Dhodapkar, Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine, Cancer Res, vol.61, pp.6451-6459, 2001.

A. Mackensen, B. Herbst, and J. L. Chen, Phase I study in melanoma patients of a vaccine with peptide-pulsed dendritic cells generated in vitro from CD34(+) hematopoietic progenitor cells, Int J Cancer, vol.86, pp.385-92, 2000.

A. Ribas, J. A. Glaspy, and Y. Lee, Role of dendritic cell phenotype, determinant spreading, and negative costimulatory blockade in dendritic cell-based melanoma immunotherapy, J Immunother, vol.27, pp.354-67, 2004.

I. Bedrosian, R. Mick, and S. Xu, Intranodal administration of peptide-pulsed mature dendritic cell vaccines results in superior CD8 + T-cell function in melanoma patients, J Clin Oncol, vol.21, pp.3826-3861, 2003.

C. Lurquin, B. Lethe, D. Plaen, and E. , Contrasting frequencies of antitumor and anti-vaccine T cells in metastases of a melanoma patient vaccinated with a MAGE tumor antigen, J Exp Med, vol.201, pp.249-57, 2005.

V. Vignard, B. Lemercier, and A. Lim, Adoptive transfer of tumor-reactive Melan-A-specific CTL clones in melanoma patients is followed by increased frequencies of additional Melan-A-specific T cells, J Immunol, vol.175, pp.4797-805, 2005.
URL : https://hal.archives-ouvertes.fr/inserm-02482064

A. Ribas, J. M. Timmerman, L. H. Butterfield, and J. S. Economou, Determinant spreading and tumor responses after peptide-based cancer immunotherapy, Trends Immunol, vol.24, pp.58-61, 2003.

H. Benlalam, N. Labarriere, and B. Linard, Comprehensive analysis of the frequency of recognition of melanoma-associated antigen (MAA) by CD8 melanoma infiltrating lymphocytes (TIL): implications for immunotherapy, Eur J Immunol, vol.31, 2001.
URL : https://hal.archives-ouvertes.fr/inserm-02482156

A. Kaiser, N. Bercovici, J. P. Abastado, and A. Nardin, Naive CD8 + T cell recruitment and proliferation are dependent on stage of dendritic cell maturation, Eur J Immunol, vol.33, pp.162-71, 2003.

S. Rutella, S. Danese, and G. Leone, Tolerogenic dendritic cells: cytokine modulation comes of age, Blood, vol.108, pp.1435-1475, 2006.

B. Birebent, R. Lorho, and H. Lechartier, Suppressive properties of human CD4 + CD25 + regulatory T cells are dependent on CTLA-4 expression, Eur J Immunol, vol.34, pp.3485-96, 2004.

D. Dieckmann, H. Plottner, S. Berchtold, T. Berger, and G. Schuler, Ex vivo isolation and characterization of CD4(+)CD25(+) T cells with regulatory properties from human blood, J Exp Med, vol.193, pp.1303-1313, 2001.

G. Zhou, C. G. Drake, and H. I. Levitsky, Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines, Blood, vol.107, pp.628-664, 2006.

G. J. Adema, I. J. De-vries, C. J. Punt, and C. G. Figdor, Migration of dendritic cell based cancer vaccines: in vivo veritas?, Curr Opin Immunol, vol.17, pp.170-174, 2005.

A. Martin-fontecha, S. Sebastiani, and U. E. Hopken, Regulation of dendritic cell migration to the draining lymph node: impact onT lymphocyte traffic and priming, J Exp Med, vol.198, pp.615-636, 2003.

F. O. Nestle, S. Alijagic, and M. Gilliet, Vaccination of melanoma patients with peptide-or tumor lysatepulsed dendritic cells, Nat Med, vol.4, pp.328-360, 1998.